Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists
- 1 August 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 30 (8) , 1101-1112
- https://doi.org/10.1111/j.1524-4725.2004.30335.x
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic DonorsJournal of Investigative Dermatology, 2002
- Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODNCellular Immunology, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathwayInternational Immunology, 1999
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Immunomodulating and antiviral activities of the imidazoquinoline S-28463Antiviral Research, 1995
- Contact immunotherapy of resistant wartsJournal of the American Academy of Dermatology, 1988
- Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalitiesJournal of the American Academy of Dermatology, 1982
- TOPICAL DNCB THERAPY FOR RESISTANT WARTSAustralasian Journal of Dermatology, 1978
- Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesionsCancer, 1970